Objective
Chronic diseases account for 75% of the disability-adjusted years in Europe and cause the premature death of 17 million people worldwide. Differences in aetiology as well as patient genetic origin, gender, age, lifestyle and biological time structure account for large variability in individual time courses of the same disease entity. Patient-tailored therapeutics is needed to prevent adverse events and improve overall therapeutic activity.
Rather than using pharmacogenomics for excluding patients from an active treatment option, TEMPO will combine functional genomics, proteomics, cell signalling, systems biology and pharmacokinetics to optimize therapeutic index in most individual patients. Thus TEMPO will determine 3 to 5 chronotherapeutics schedules with distinct temporal delivery patterns of the same anticancer drug. Each schedule is adjusted to a different dynamic class of temporal genomics and phenomics parameters related to interwoven circadian and cell division cycles and drug metabolism. In vivo, in vitro, in silico approaches are integrated through the multidisciplinary excellence in the consortium.
TEMPO will offer a proof of principle of tailored chronotherapeutics in mouse models for irinotecan, an active drug against colorectal cancers, and for seliciclib, currently in clinical testing. TEMPO will gather the corresponding human prerequisites and technology for subsequent application to patients. Three SMEs play a pivotal role for the impact of TEMPO on European health, economics and society. Novel and complementary in silico dynamic models of coordinated clock, cell cycle and pharmacology pathways will identify new therapeutic targets and delivery schedules of active molecules, thus improve drug development processes. New tools will enable personalized medicine to integrate the time dimension in routine implementation. TEMPO will reduce both therapeutic variability and attrition rates two major impediments for human health and pharmaceutical industry...
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- natural sciences biological sciences cell biology cell signaling
- medical and health sciences clinical medicine oncology colorectal cancer
- medical and health sciences health sciences personalized medicine
- medical and health sciences basic medicine pharmacology and pharmacy pharmacokinetics
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-LIFESCIHEALTH-7
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
PARIS
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.